Host: |
Goat |
Applications: |
Pep-ELISA/WB/IHC |
Reactivity: |
Human/Pig |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Goat polyclonal antibody anti-KLF8/BKLF3 (N-Term) is suitable for use in ELISA, Western Blot and Immunohistochemistry research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
Concentration: |
0.5 mg/mL |
Dilution Range: |
IHC-3.75µg/mlELISA-antibody detection limit dilution 1:32000. |
Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
Gene Symbol: |
KLF8 |
Gene ID: |
11279 |
Uniprot ID: |
KLF8_HUMAN |
Immunogen Region: |
N-Term |
Accession Number: |
NP_009181.2; NP_001152768.1 |
Specificity: |
This antibody is expected to recognise isoform 1 (NP_009181.2) and isoform 2 (NP_001152768.1). |
Immunogen Sequence: |
VDMDKLINNLEVQ |
Post Translational Modifications | Sumoylation at Lys-67 represses transcriptional activity and reduces cell cycle progression into the G(1) phase. Has no effect on subcellular location. |
Function | Transcriptional repressor and activator. Binds to CACCC-boxes promoter elements. Also binds the GT-box of cyclin D1 promoter and mediates cell cycle progression at G(1) phase as a downstream target of focal adhesion kinase (FAK). |
Protein Name | Krueppel-Like Factor 8Basic Krueppel-Like Factor 3Zinc Finger Protein 741 |
Cellular Localisation | Nucleus |
Alternative Antibody Names | Anti-Krueppel-Like Factor 8 antibodyAnti-Basic Krueppel-Like Factor 3 antibodyAnti-Zinc Finger Protein 741 antibodyAnti-KLF8 antibodyAnti-BKLF3 antibodyAnti-ZNF741 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance